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The robustness and safety of liver-directed gene therapy 
can be substantially improved by enhancing expres-
sion of the therapeutic transgene in the liver. To achieve 
this, we developed a new approach of rational in silico 
vector design. This approach relies on a genome-wide 
bio-informatics strategy to identify cis-acting regulatory 
modules (CRMs) containing evolutionary conserved clus-
ters of transcription factor binding site motifs that deter-
mine high tissue-specific gene expression. Incorporation 
of these CRMs into adeno-associated viral (AAV) and 
non-viral vectors enhanced gene expression in mice liver 
10 to 100-fold, depending on the promoter used. Fur-
thermore, these CRMs resulted in robust and sustained 
liver-specific expression of coagulation factor IX (FIX), 
validating their immediate therapeutic and translational 
relevance. Subsequent translational studies indicated 
that therapeutic FIX expression levels could be attained 
reaching 20–35% of normal levels after AAV-based liver-
directed gene therapy in cynomolgus macaques. This 
study underscores the potential of rational vector design 
using computational approaches to improve their 
robustness and therefore allows for the use of lower and 
thus safer vector doses for gene therapy, while maximiz-
ing therapeutic efficacy.
Received 4 April 2014; accepted 9 June 2014; advance online  
publication 5 August 2014. doi:10.1038/mt.2014.114
INTRODUCTION
Convincing evidence continues to emerge from clinical trials that 
gene therapy is yielding therapeutic effects in patients suffering 
from a wide range of diseases.1,2 In particular, liver-directed gene 
therapy is becoming a promising modality to obtain sustained 
hepatocyte-specific expression of secreted factors into the cir-
culation. This has implications for other liver-borne genetic and 
complex diseases. Despite these successes, there have been con-
cerns regarding the efficacy and safety of some gene delivery 
approaches. The major limiting factors are insufficient and/or 
transient transgene expression levels and inappropriate expres-
sion of the transgene in unwanted cell types. Higher vector 
doses are typically used in gene therapy clinical trials to improve 
 therapeutic efficacy. However, this often triggers T-cell–mediated 
immune responses against the vector capsid antigens displayed by 
transduced cells, particularly hepatocytes, in the context of MHC 
class I.3–5 This contributes to the elimination of the gene-modified 
cells and liver toxicity, resulting in short-term gene expression. 
Moreover, inadvertent transgene expression in antigen-presenting 
cells (APCs), increases the risk of untoward immune responses 
against the gene-modified hepatocytes and/or the therapeutic 
transgene product.6,7 Hence, there is a need to generate improved 
gene therapy vectors allowing the use of lower and safer vector 
doses that enable sustained hepatocyte-specific expression of the 
therapeutic gene.
Typically, conventional methods of vector design rely on 
haphazard trial-and-error approaches whereby transcriptional 
enhancers are combined with promoters to boost expression 
 levels. Though this can sometimes be effective,6,8 it often results in 
non-productive combinations that result in either modest or no 
increased expression levels of the gene of interest in hepatocytes 
and/or loss of liver specificity.6 An intrinsic bias associated with 
the design of gene therapy vectors is that it frequently relies on 
the in vitro characteristics of its regulatory elements in cell lines, 
which is usually not predictive of their in vivo performance.6,9 
Moreover, these conventional approaches in vector design do 
not take into account the importance of including evolutionary 
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Figure 1 Nucleotide sequence of the HS-CRM8 element located with the promoter of human Serpina1. This HS-CRM8 element is the most 
potent HS-CRM that was identified by the hydrodynamic transfection screen (see Figure 3). The evolutionary conservation is highlighted and the 
TFBS are shown. The TFBS include binding sites for LEF-1 (brown), LEF-1/TCF (dark green), CEBP (yellow), FOXA1 (light blue), HNF1 (light green), 
and MyoD (purple).
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conserved regulatory motifs into the expression modules, which 
is particularly relevant for clinical translation.
In silico design offers unique opportunities to generate robust 
liver-specific gene therapy vectors and overcome some of the limi-
tations of conventional gene therapy vector development. Though 
data-mining has been used to identify cis-regulatory modules 
(CRMs) and analyze expression patterns in vivo,10,11 surprisingly 
however, this area of research remains largely unexplored in the 
context of vector development and gene therapy. To address this 
caveat and overcome some of the limitations of conventional vec-
tor design, we have developed and validated an alternative strat-
egy to generate efficient, liver-specific gene therapy vectors using 
computational methods. In this study, we relied on a genome-
wide in silico identification of CRMs that contained clusters of 
evolutionarily conserved transcription factor binding site (TFBS) 
motifs associated with robust hepatocyte-specific expression. We 
employed a comprehensive computational strategy that takes into 
account not only the over-representation of a given TFBS but also 
its context-dependent co-occurrence with other TFBS.12 Such an 
approach has not yet been used to improve the performance of 
gene therapy vectors, which underscores the novelty of this study. 
This computational approach has broad implications for liver-
directed gene therapy and allows for the use of lower and thus 
safer vector doses, while maximizing therapeutic efficacy in pre-
clinical mouse models and in non-human primates. Furthermore, 
the validation of these liver-specific CRMs provides new insights 
into the molecular determinants underlying transcriptional con-
trol in hepatocytes.
RESULTS
Computational de novo design of liver-specific CRMs
Rational de novo design of robust liver-specific gene therapy vec-
tors relies on the identification of tissue-specific CRMs associated 
with high hepatocyte-specific expression. To identify these criti-
cal hepatocyte-specific CRMs (i.e., HS-CRMs), we used a multi-
step computational approach. This bio-informatics approach 
was originally used to identify CRMs associated with differential 
gene expression in response to in vitro stimuli.12 In this study, we 
extended this computational approach to identify evolutionary 
conserved CRMs associated with highly expressed liver-specific 
promoters. One of the unique features of this computational strat-
egy is that it takes into account the over-representation of a given 
TFBS and its context-dependent co-occurrence with other TFBS 
on a genome-wide scale.12
A total of 14 different HS-CRMs were identified, ranging in size 
from 41 bp to 551 bp (Figure 1 and Table 1 and Supplementary 
Figure S1 and Table S2). The HS-CRM comprised putative bind-
ing sites for eight different TFs: HNF1α, C/EBP, LEF1, FOX, 
IRF, LEF1/TCF, Tal1β/E47, and MyoD. These HS-CRMs con-
tain a “molecular signature” that represents a hallmark of highly 
expressed genes in the liver. We observed that most HS-CRMs 
contain multiple TFBS that are similar but the uniqueness of each 
HS-CRM is dictated by its specific arrangement of the TFBS. Since 
all HS-CRMs exhibited a high degree of phylogenetic conservation 
among 44 divergent species, this suggests a strong evolutionary 
selective pressure to maintain these particular TFBS combinations 
for high tissue-specific expression. Phylogenetic conservation also 
increases the likelihood that the performance of the HS-CRMs is 
preserved across species in the process of clinical translation.
In vivo validation of hepatocyte-specific CRMs
We subsequently assessed the efficiency and specificity of these 
novel HS-CRMs in liver. We first expressed human clotting factor 
IX (hFIX) from a chimeric promoter, composed of a potent liver-
specific minimal transthyretin promoter (TTR) in conjunction 
with the different HS-CRM (Figure 2a). We choose hydrodynamic 
Table 1 TFBS strongly associated with high liver-specific expression
Name Gene Length (bp) TFBS association Accession numberb
HS-CRM1 Alb 101 HNF1, CEBP, LEF-1, FOX NM_000477.5
HS-CRM2 Apoc4 71 FOX, CEBO, HNF-1 NM_001646.2
HS-CRM3 Apoh 173 IRF, HNF1, FOX, CEBP NM_000042.2
HS-CRM4 Apoh 551 CEBP, HNF1, LEF-1/TCF, FOX, Tal1β/E47, IRF NM_000042.2
HS-CRM5 Cyp2e1 141 CEBP, HNF1, LEF-1, LEF-1/TCF, MyoD, IRF, FOX NM_000773.3
HS-CRM6 Aldob 135 CEBP, HNF1, IRF, FOX, LEF1/TCF, MyoD NM_000035.3
HS-CRM7 Apoc1 94 FOX, CEBP, LEF-1, LEF-1/TCF, MyoD, HNF1 NR_028412.1
HS-CRM8 Serpina1a 72 HNF1, FOX, CEBP, MyoD, LEF-1, LEF-1/TCF NM_000295.4
HS-CRM9 Tf 171 CEBP, HNF1, LEF-1, LEF-1/TCF, FOX, Tal1β/E47, IRF, MyoD NM_001063.3
HS-CRM10 Ttr 170 HNF1, CEBP, FOX, LEF-1, LEF-1/TCF, MyoD NM_000371.3
HS-CRM11 Fga 74 CEB P, HNF1, LEF-1, LEF-1/TCF, MyoD NM_000508.3
HS-CRM12 Hpr 441 CEBP, HNF1, LEF-1, LEF-1/TCF, FOX, Tal1β/E47, IRF, MyoD NM_020995.3
HS-CRM13 Serpina1a 88 HNF1, CEBP, LEF-1/TCF NM_000295.4
HS-CRM14 Serpina1a 41 HNF1, MyoD, Tal1β/E47 NM_000295.4
Evolutionary conserved HS-CRM enriched in TFBS associated with high liver-specific expression. The HS-CRM designation, corresponding gene, size (in bp) and TFBS 
clusters are shown.
HS-CRM, hepatocyte-specific cis-acting regulatory module; TFBS, transcription factor binding sites.
aHS-CRM present at different locations within the same promoter of a given gene bGenBank (http://www.ncbi.nlm.nih.gov/nuccore).
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delivery to screen the 14 different hepatocyte-specific cis-regula-
tory modules (HS-CRMs) since it allows for a rapid and reliable 
assessment of their in vivo performance, without having to pro-
duce AAV vectors for each of them. Only the best HS-CRM was 
then selected for a subsequent comprehensive characterization in 
an AAV vector context (see below). Semi-high throughput hydro-
dynamic transfection of these expression plasmids into C57BL/6 
mice revealed that the large majority (i.e., 85%) of the de novo 
designed HS-CRMs resulted in a significant increase in hFIX 
expression (Figure 3a). In particular, the most potent HS-CRM8 
resulted in a robust improvement in hFIX expression, yielding 
up to 2.5 µg/ml. We subsequently validated the HS-CRM8 ele-
ment in AAV9-based vectors in which the hFIX gene was driven 
from either a moderately active (Palm) (Figure 3b) or potent liver 
promoter (TTR) (Figure 3c). The de novo designed HS-CRM8 
element in the AAV vector resulted in a robust and sustained 
100-fold increase in hFIX expression from the moderately active 
Palm promoter (P < 0.0001) (5 × 1011 vg, Figure 3b). Moreover, 
this HS-CRM8 element significantly improved hFIX expres-
sion seven- to tenfold (P < 0.00005), even when a potent liver-
specific promoter was used like TTR (Figure 3c), consistent with 
the increased hFIX expression after hydrodynamic transfection 
(Figure 3a). This resulted in stable therapeutic hFIX expression 
levels of about 100%, even at relatively low vector doses (5 × 109 
vg). The HS-CRM8 element increased transcription from both 
TTR and Palm promoters (Supplementary Figure S2a,b). The 
increased hFIX antigen levels correlated strongly with the FIX 
mRNA levels (Supplementary Figure S2c). There was no signifi-
cant difference in vector copy number in mice injected with the 
vectors with or without the HS-CRM8 element (Supplementary 
Figure S2d). The vector copy number correlated with the vector 
doses.
The potency of the HS-CRM8 element was subsequently 
 evaluated through assessment of phenotypic correction in hemo-
philic FIX-deficient mice following a tail-clip injury. The treated 
mice survived the injury in contrast to naive controls, consistent 
with a significant dose-dependent reduction in blood loss (naive 
mice: 1,167 ± 215 µl; 5 × 109 vg/mouse: 596 ± 92 µl (P < 0.0005); 
2 × 1010 vg/mouse: 495 ± 82 µl (P < 0.00005). hFIX mRNA expres-
sion was restricted to the liver (Figure 3d,e), even upon admin-
istration of extremely high vector doses (3 × 1012 vg), despite the 
detection of viral genomes in non-hepatic tissues (i.e., heart, 
spleen, muscle, etc.) (data not shown).
To further enhance hFIX expression from the HS-CRM8-
TTR-FIX construct, we subsequently replaced hFIX Intron A with 
an MVM intron upstream of the hFIX transgene (Figure 2c) or 
its codon-optimized equivalent (hFIXco) (Figure 2d). Each of 
these changes led to a significant increase in hFIX expression 
(Figure 4a,b). This optimized HS-CRM8-TTR-MVM-FIXco con-
struct was then packaged into scAAV for subsequent validation in 
a non-human primate model.
Preclinical validation of efficacy and safety in non-
human primates
The scAAV9-HS-CRM8-TTR-MVM-hFIXco vector was 
injected into two cynomolgus macaques (OUG6 and OBEV7) 
at a dose of 9 × 1011 vg/kg. There was a steady increase in the 
circulating hFIX protein in both animals that reached a peak by 
week 4, corresponding to 1,718 ng/ml and 885 ng/ml for OUG6 
and OBEV7, respectively (Figure 5a). These levels correspond 
to therapeutic FIX levels in the 20–35% range of normal FIX 
levels. After a few weeks, the hFIX transgene expression began 
to decline (Figure 5a), which could be ascribed to the induction 
of anti-hFIX antibodies (Figure 5c,d), often seen in non-human 
primates following AAV liver gene transfer,13,14 despite the use 
of liver-specific promoters. The AAV9 vector administration 
also triggered anti-AAV9 neutralizing antibodies (Figure 5b). 
Both animals had consistent coagulation parameters despite 
the occurrence of hFIX inhibitory antibodies (Supplementary 
Figure S3). This indicates that the anti-hFIX antibodies did not 
cross-react with the macaque FIX. The animals did not develop 
any adverse events or toxicity (Supplementary Figures S4 and 
S5). Human FIX mRNA expression was restricted to the liver 
whereas only background levels were apparent in any other 
organ or tissue tested (Figure 6a). This confirms the liver-spec-
ificity of the synthetic in silico designed HS-CRM8-TTR pro-
moter, consistent with the mouse data (Figure 3d,e). The AAV9 
vector resulted predominately in liver transduction though sig-
nificant gene transfer was also apparent in heart, lungs, spleen, 
kidney and brain (Figure 6b).
Figure 2 Schematic representation of vectors used. (a) AAV9-HS-
CRM-TTR-FIX, (b) AAV9-HS-CRM-PALM-FIX, (c) AAV9-HS-CRM8-TTR-
FIX, and (d) AAV9-HS-CRM8-TTR-FIXco. The expression cassettes in a–b 
were packaged in a single-stranded AAV9, flanked by the 5′ and 3′ AAV 
inverted terminal repeats (ITR). (a) The liver-specific minimal transthyre-
tin (TTR) promoter drives the human FIX minigene. Alternatively, (b) a 
Palm (paralemmin) promoter was used that was only weakly expressed 
in liver to drive the FIX mini-gene. The hepatocyte-specific CRMs (i.e., 
HS-CRM1 to HS-CRM14) are located upstream of the (a) TTR promoter. 
Similarly, HS-CRM8 is located upstream of the (b) Palm promoter. The 
FIX first intron (intron A) and polyadenylation sites (pA) are also indicated. 
The control vectors AAV9-TTR-FIX and AAV9-Palm-FIX are identical to 
AAV9-HS-CRM8-TTR-FIX and AAV9-HS-CRM8-Palm-FIX, respectively, 
except for the absence of any HS-CRM elements. The vectors (c) AAV9-
HS-CRM8-TTR-FIX and (d) AAV9-HS-CRM8-TTR-FIXco were packaged in 
a self-complimentary AAV9. Both vectors had a small MVM (minute virus 
of mice) intron cloned upstream of the hFIX gene.
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One of our animals (OUG6) was euthanized due to unex-
pected complications unrelated to the gene therapy, which 
occurred after a surgical procedure to obtain a liver biopsy. We 
subsequently tried to eliminate the anti-hFIX inhibitors in the 
remaining animal (OBEV7) following, transient immunosuppres-
sion with cyclosporin (CsA) and Rituximab (Rtx). This led to a 
Figure 3 In vivo validation of HS-CRMs. (a) Semi-high throughput HS-CRM screening in vivo after intravenous hydrodynamic liver-directed injection 
with pAAV-HS-CRM-TTR-FIX and pAAV-TTR-FIX plasmids at a dose of 2 µg DNA. Significant differences compared to the control without HS-CRM were 
indicated (t-test, *P ≤ 0.05, mean ± SD). (b) FIX expression levels after intravenous administration of AAV9-HS-CRM8-Palm-FIX and AAV9-Palm-FIX 
(1 × 1011 vg/mouse) (n = 5 per cohort, C57Bl/6). The difference in FIX expression levels was significant (t-test, *P ≤ 0.0001). (c) FIX expression levels 
after intravenous administration of AAV9-HS-CRM8-TTR-FIX and AAV9-TTR-FIX control vectors (5 × 109 vg/mouse) (n = 5 per cohort, C57Bl/6). The 
difference in FIX expression levels was significant (t-test, *P ≤ 0.00005). FIX levels were determined using a hFIX-specific ELISA. (d) Hepatocyte-
specificity of AAV9 containing HS-CRM8. RT-PCR analysis on 20 ng total RNA from different organs of C57/Bl6 mice (n = 3) injected intravenously with 
AAV9-HS-CRM8-TTR-FIX vectors (3 × 1012 vg/mouse); RNA liver samples were amplified with and without RT to exclude genomic DNA amplification. 
Amplification of hFIX mRNA was not detectable in these control samples without RT (data not shown). (e) Corresponding qRT-PCR analysis of hFIX 
mRNA levels in the different organs expressed relative to hFIX mRNA levels in the liver. Expression levels (mean ± SD) relative to liver are shown. H2O, 
water control; MW, molecular weight marker; PBS liver, liver sample of PBS-injected control mice; RT, reverse transcription.
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modest increase in circulating FIX levels (Figure 5a), consistent 
with a decrease in anti-hFIX antibodies (Figure 5c,d). This was 
consistent with the profound decrease in CD20+ B cells (Figure 
5e), whereas the percentage of CD3+ T cells remained unaffected 
(Figure 5f). Unfortunately, only partial and transient immuno-
suppression could be achieved, since the animal refused to ingest 
CsA after the initial treatment. Transient immunosuppression 
also led to transient and partial decline in anti-AAV9 neutralizing 
antibodies (Figure 5b).
DISCUSSION
In this study, we have validated a computational approach to 
improve the performance of current gene therapy vectors. Our 
data provide evidence that evolutionary conserved clusters of 
TFBS motifs corresponding to hepatocyte-specific CRMs could 
be identified in silico that are strongly associated with robust 
liver-specific expression in vivo. We discovered that the selected 
HS-CRMs identified contain a “molecular signature” composed of 
TFBS clusters that represent a hallmark of highly expressed genes 
in the liver. We demonstrated that these HS-CRMs resulted in a 
substantial increase in transgene expression in the liver after gene 
therapy, while maintaining a high degree of tissue-selectivity. In 
particular, a significant 10- to 100-fold increase in gene expres-
sion could be obtained depending on the type of HS-CRM and 
promoter used. The increased protein expression levels were con-
sistent with an increased transcriptional activity. We subsequently 
validated the potential of these hepatocyte-specific HS-CRMs in 
a clinically relevant therapeutic setting and demonstrated robust 
Figure 4 Optimization of the HS-CRM8-TTR-hFIX construct. The (a) 
pAAV-HS-CRM8-TTR-MVM-hFIX or (b) pAAV-HS-CRM8-TTR-FIXIA and (a,b) 
pAAV-HS-CRM8-TTR-MVM-hFIXco plasmids were hydrodynamically trans-
fected into C57BL/6 mice at doses of (a) 2 µg/mouse or (b) 0.5 µg/mouse. 
FIX expression was measured using a hFIX-specific ELISA (n = 4) on plasma 
samples collected 1 or 2 days after transfection (**P < 0.01; ***P < 0.001).
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Figure 5 Preclinical validation of efficacy and safety in non-human primates. The scAAV9-HS-CRM8-TTR-MVM-hFIXco vector was injected in two 
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and sustained supra-physiologic expression levels of coagulation 
FIX following hepatic transduction with AAV vectors. The use of 
these potent HS-CRMs therefore allows for the use of lower and 
thus safer vector doses in gene therapy clinical trials, that may 
in turn reduce the risk of developing T-cell–mediated immune 
responses against the vector antigens displayed on the transduced 
target cells.1–5 In silico vector design may therefore pave the way 
towards a more rational and comprehensive strategy for vector 
optimization with broad implications to improve the efficacy and 
safety of gene therapy. Indeed, we have confirmed the superior-
ity of the HS-CRM8 expression module for liver-directed gene 
therapy using other transgenes (i.e., factor VIII, phenylalanine 
hydroxylase; ref. 15 and data not shown) Another advantage of 
these CRMs is their small size so that they can be readily accom-
modated into viral vectors in conjunction with relatively large 
therapeutic transgenes. The use of hyper-active FIX transgenes 
can further enhance vector performance.16,17
We subsequently validated the efficacy and safety of the AAV-
FIX vectors containing the most potent HS-CRM8 expression 
module in a non-human primate model. Systemic vector admin-
istration resulted in robust therapeutic FIX levels in the 20–35% 
range at clinically relevant vector doses (9 × 1011 vg/kg). This is 
consistent with the high vector copy number in the liver biopsies. 
Exhaustive safety testing revealed no significant adverse effects. 
The performance of our vector compared favorably with that 
of one of the most potent AAV vectors that was used in a clini-
cal trial in patients suffering from severe hemophila B.3 Subjects 
injected with 6 × 1011 vg/kg, comparable to the dose used in our 
primate study, resulted in ~1–3% FIX. In those subjects injected 
with higher vectors doses (i.e., 2 × 1012 vg/kg), ~10% FIX could 
be obtained.3 Previously, we had assessed the performance of the 
same clinical trial vector in cynomolgus macaques.13 When cali-
brating the vector doses, it would appear that our current vector 
design is about tenfold more efficient. Since a human FIX trans-
gene was employed, it is known that this could potentially evoke 
neutralizing and non-neutralizing anti-hFIX antibodies in non-
human primate models.13 This is consistent with our observations 
that anti-hFIX antibodies were detected in the recipients which 
accounted for the subsequent decline in FIX expression. This pro-
vided us with an opportunity to test whether we could restore FIX 
by transient immunosuppression using rituximab and CsA. FIX 
could be detected after immune-suppression, even up to nearly 
2 years after gene transfer. This suggests that the FIX-transduced 
hepatocytes persisted long-term and that the short-term FIX 
expression was primarily due to a humoral immune response. 
Our results caution that rituximab by itself may not suffice to treat 
Figure 6 Expression biodistribution and transduction efficiency analysis in non-human primates. (a) Expression was analyzed by qRT-PCR and 
(b) biodistribution and transduction efficiency in different organs was determined by qPCR. Background signals from non-injected animals were 
subtracted from the experimental values.
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patients that develop inhibitory antibodies after gene therapy and 
that more complex combination therapies may be required to 
achieve optimal immune suppression.
In this study, we choose to employ AAV9 instead of AAV8. 
Previously, Gao et al. evaluated the relationship of phylogenetic 
relatedness of distinct AAV serotypes and serologic activity.18 
Polyclonal antisera generated against AAV2 cross-reacted to 
a lesser extent with AAV9 than with AAV8. Conversely, poly-
clonal antisera generated against AAV9 cross-reacted to a lesser 
extent with AAV2 than when the polyclonal antisera were gen-
erated against AAV8. These experiments suggest that it may be 
desirable to select AAV9 over AAV8 to overcome neutralization 
by pre-existing anti-AAV2 antibodies in human subjects, which 
represents an important bottleneck in clinical trials. Moreover, 
we choose to explore AAV9 since the bio-distribution had not 
systematically been analyzed in non-human primates. Finally, 
we had previously conducted a side-by-side comparison between 
AAV8 and AAV9 and found that AAV9 transduced the liver just 
as efficiently as AAV8 in mice.19
The advantage of this particular computational approach 
used to identify the tissue-specific CRMs compared to other in 
silico approaches was discussed previously.12 One particularly 
distinctive feature is that it identifies not only the TFBS that are 
over-represented in liver-specific CRMs but also allows for the 
identification of frequently co-occurring TFBS. Consequently, 
this in silico analysis is more comprehensive and allows for the 
identification of TFBS elements that tend to cluster together in 
CRMs of genes that are highly expressed in a given target tissue 
(in casu liver). It therefore takes into account the actual context-
dependent TFBS interactions from a broad genome-wide per-
spective, instead of just relying on the over-representation of a 
single TFBS element.12 Our previous studies had shown that the 
present computational approach was more reliable, compared 
to other data-mining strategies that typically rely solely on the 
over-representation of a given TFBS, regardless of its context. 
The current in silico strategy that defines the HS-CRMs has been 
further improved by taking into account cross-species evolution-
ary conservation of the TFBS clusters. This approach is more 
comprehensive and increases the likelihood that the superior 
performance of the HS-CRMs is maintained in patients undergo-
ing gene therapy, consistent with the robust FIX levels obtained 
in the non-human primate model. In addition, this study goes 
beyond the initial description and validation of the algorithm12 
and establishes a bona fide causal relationship between the pres-
ence of these evolutionary conserved TFBS clusters and high 
liver-specific expression. In contrast, the previously published 
bioinformatics approach was applied in a different context and 
merely established correlations between TFBS clusters and differ-
entially expressed genes following a given physiologic  stimulus. 
However, that study did not provide direct proof of the impact 
of such TFBS clusters on gene expression levels. This study 
addresses this caveat by direct in vivo gene transfer, hereby pro-
viding experimental in vivo validation of the bioinformatics algo-
rithm. Though the majority of HS-CRMs resulted in a significant 
increase in gene expression, a few elements had only limited 
impact. This suggests that other unknown factors may influence 
gene expression, such as the spacing between a given HS-CRM 
and the promoter/TATA box or epigenetic factors and chromatin 
remodeling. This study sets the stage to further refine the in silico 
analysis to improve gene therapy vectors. Moreover, the most 
potent HS-CRM8 could be used in conjunction with other liver-
specific promoters, beyond those characterized in this study.
This study has broad implications for the design of better gene 
therapy vectors that target different diseases. The same principle 
could be applied to other vectors24 or to other organs, tissues or 
promoters, which we have validating experimentally in heart and 
skeletal muscle (Rincon MY, Sarcar S, Danso-Abeam D, Keyaerts 
M, Matrai J, Samara-Kuko E, et al. unpublished data). This may 
ultimately impact not only on the clinical translation of gene ther-
apy but also on fundamental biological and transgenic studies that 
rely on the use of robust tissue-specific gene expression.
MATERIALS AND METHODS
Extended methods are available in the Supplementary Methods. The 
accession numbers of the genes from which the hepatocyte-specific CRMs 
(i.e., HS-CRM1 to 14) are derived are listed in Table 1.
Identification of hepatocyte-specific CRMs. To identify the hepatocyte-
specific (HS)-CRMs (Figure 1 and Table 1 and Supplementary Figure 
S1 and Table S1), we used a step-wise in silico strategy: (i) we first identi-
fied liver-specific genes that are highly expressed in the liver based on 
statistical analysis of micro-array expression data of normal human tis-
sues;20,21 (ii) we then extracted the corresponding promoter sequences up 
to 800 bp upstream of the transcriptional start site (TSS) from public da-
tabases (NCBI36/hg18 genome assembly); (iii) using the TRANSFAC da-
tabase we subsequently mapped TFBS elements to these promoters. We 
then identified the tissue-specific CRM using a multidimensional scaling 
(MDS)/ differential distance matrix (DDM) approach, as described;12 (iv) 
Finally, the cross-species conservation was taken into consideration to 
identify highly conserved HS-CRMs.
Generation of CRM constructs. The different HS-CRMs (Table 1 and 
Supplementary Table S1) were synthesized by conventional oligonucle-
otide synthesis and cloned upstream of the liver-specific minimal trans-
thyretin (TTR) (Figure 2a) or paralemmin (Palm) promoters (Figure 2b), 
driving the expression of the factor IX (FIX) mini-gene.9 Alternatively, the 
TTR promoter coupled to the HS-CRM8 element was used to drive wild-
type FIX (Figure 2c) or its codon-optimized counterpart (Figure 2d) in 
the context of a self-complementary (sc) AAV backbone.22 These vectors 
also contained a minute virus of mice (MVM) mini-intron. Cloning de-
tails are available upon request.
AAV vector production and purification. Hepatotropic AAV9 vectors 
were prepared and purified, as previously described.19 AAV vectors were 
purified by cesium chloride gradient ultracentrifugation. Vector titers 
were determined by quantitative (q) PCR (see Supplementary Methods).
Animal procedures. Wild-type or hemophilic mice23 were transfected 
hydrodynamically with plasmids or injected intravenously with purified 
AAV9 vectors. hFIX antigen levels were assayed in citrated mouse plas-
ma using a hFIX-specific enzyme-linked immunosorbent assay (ELISA). 
Hemophilic mice were subjected to a tail-clipping assay.7,19 The scAAV9-
HS-CRM8-TTR-MVM-hFIXco vector (Figure 2d) (9 × 1011 vg/kg) was 
intravenously injected in cynomolgus macaques. Animals were subjected 
to transient immune suppression by cyclosporine A (CsA) and rituximab 
treatment.13 Immunological analysis, hFIX antigen, anti-AAV9 capsid 
IgG, anti-hFIX IgG and Bethesda assays are described in Supplementary 
Methods. Gene expression levels were evaluated by qRT-PCR and nor-
malized to mRNA levels of the endogenous monkey GAPDH gene. 
Transduction efficiency was determined by qPCR and transgene copy 
numbers were determined as described previously.19
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SUPPLEMENTARY MATERIAL
Figure S1. Nucleotide sequence of the HS-CRM elements (HS-CRM1 
to HS-CRM14).
Figure S2. Hepatic hFIX mRNA levels and AAV copy numbers follow-
ing intravenous injection of AAV9-FIX vectors in C57/Bl6 mice (n = 3).
Figure S3. Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene 
therapy in non-human primates: analysis of coagulation parameters.
Figure S4. Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco gene 
therapy in non-human primates: analysis of hematological parameters.
Figure S5. Safety analysis of scAAV9-HS-CRM8-TTR-MVM-hFIXco 
gene therapy in non-human primates: blood chemistry.
Table S1. Evolutionary conserved HS-CRMs enriched in TFBS associ-
ated with high liver-specific expression.
Methods.
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